A major advancement in the treatment of generalized myasthenia gravis (gMG) is expanding options for patients worldwide, supported by the leadership of UNC Neurology’s Dr. James F. Howard Jr.
The U.S. Food and Drug Administration recently approved an expanded indication for efgartigimod (VYVGART®), making it available to all adult patients with gMG regardless of antibody status. This milestone follows results from the Phase 3 ADAPT SERON study—the largest clinical trial to date focused on patients without detectable acetylcholine receptor antibodies.
Dr. Howard, Professor of Neurology at the UNC School of Medicine, served as a global lead investigator in the clinical development program. Under his leadership, the ADAPT SERON trial demonstrated that targeting pathogenic IgG can lead to meaningful and sustained symptom improvement across multiple gMG subtypes, including those with historically limited treatment options.
This achievement highlights UNC Neurology’s continued role at the forefront of international clinical research and its commitment to advancing innovative therapies that improve patients’ lives.